AR094494A1 - Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento - Google Patents
Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamientoInfo
- Publication number
- AR094494A1 AR094494A1 ARP140100151A ARP140100151A AR094494A1 AR 094494 A1 AR094494 A1 AR 094494A1 AR P140100151 A ARP140100151 A AR P140100151A AR P140100151 A ARP140100151 A AR P140100151A AR 094494 A1 AR094494 A1 AR 094494A1
- Authority
- AR
- Argentina
- Prior art keywords
- substituted
- methyl
- unsubstituted
- pyrazol
- pirrolopirimidins
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Abstract
Reivindicación 1: Un compuesto de la fórmula (1) y las sales, tautómeros, estereoisómeros, enantiómeros, e isotopólogos del mismo aceptables desde el punto de vista farmacéutico, en donde: R¹ es alquilo C₁₋₈ sustituido o no sustituido, cicloalquilo C₃₋₈ sustituido o no sustituido, o heterociclilo no aromático sustituido o no sustituido; R² es arilo sustituido o no sustituido, o heteroarilo sustituido o no sustituido; R³ es heterociclilo sustituido o no sustituido o arilo sustituido o no sustituido; y L es NH u O; siempre que R³ no sea piridilo cuando L es NH o cuando R² es pirazolilo; y el compuesto no es N-metil-N-[trans-3-[[5-(1-metil-1H-pirazol-4-il)-2-[(1-metil-1H-pirazol-4-il)amino]-7H-pirrolo[2,3-d]pirimidin-4-il]oxi]-ciclobutil]-2-propenamida; o N-metil-N-[trans-3-[[5-(1-metil-1H-pirazol-3-il)-2-[(1-metil-1H-pirazol-4-il)amino]-7H-pirrolo[2,3-d]pirimidin-4-il]oxi] ciclobutil]-2-propenamida.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361753259P | 2013-01-16 | 2013-01-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR094494A1 true AR094494A1 (es) | 2015-08-05 |
Family
ID=50031611
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP140100151A AR094494A1 (es) | 2013-01-16 | 2014-01-15 | Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento |
Country Status (24)
Country | Link |
---|---|
US (3) | US9346812B2 (es) |
EP (2) | EP2945636B1 (es) |
JP (1) | JP2016505041A (es) |
KR (1) | KR20150108389A (es) |
CN (1) | CN105188704B (es) |
AR (1) | AR094494A1 (es) |
AU (1) | AU2014207641A1 (es) |
BR (1) | BR112015016997A2 (es) |
CA (1) | CA2897985A1 (es) |
CL (1) | CL2015001990A1 (es) |
EA (1) | EA201591327A1 (es) |
EC (1) | ECSP15030799A (es) |
ES (1) | ES2638179T3 (es) |
HK (1) | HK1212207A1 (es) |
IL (1) | IL239901A0 (es) |
MX (1) | MX2015009209A (es) |
NI (1) | NI201500094A (es) |
NZ (1) | NZ630467A (es) |
PE (1) | PE20151995A1 (es) |
PH (1) | PH12015501576A1 (es) |
SG (1) | SG11201505446WA (es) |
TW (1) | TW201441227A (es) |
WO (1) | WO2014113429A2 (es) |
ZA (1) | ZA201505011B (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH12017500997A1 (en) | 2012-04-04 | 2018-02-19 | Samumed Llc | Indazole inhibitors of the wnt signal pathway and therapeutic uses thereof |
SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
KR20170024120A (ko) | 2014-07-14 | 2017-03-06 | 시그날 파마소티칼 엘엘씨 | 치환된 피롤로피리미딘 화합물을 사용한 암의 치료방법, 이의 조성물 |
US10611765B2 (en) | 2014-11-06 | 2020-04-07 | Ohio State Innovation Foundation | Pyrrolopyrimidine derivatives as Mps1/TTK kinase inhibitors |
CA2976109A1 (en) | 2015-02-13 | 2016-08-18 | Dana-Farber Cancer Institute, Inc. | Substituted pyrrolopyrimidine, pyrazolopyrimidine and purine derivatives and use thereof as lrrk2 inhibitors |
CN105906630B (zh) * | 2015-04-06 | 2018-10-23 | 四川百利药业有限责任公司 | 用作fgfr抑制剂的n-(1h-吡唑-5-基)嘧啶并吡唑-4,6-二取代胺类化合物 |
KR20180015160A (ko) * | 2015-06-22 | 2018-02-12 | 오노 야꾸힝 고교 가부시키가이샤 | Brk 저해 화합물 |
WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
EP3336090B1 (en) * | 2015-08-13 | 2020-07-22 | Beijing Hanmi Pharmaceutical Co., Ltd. | Irak4 inhibitor and use thereof |
JP2018538241A (ja) | 2015-10-13 | 2018-12-27 | ザ スクリプス リサーチ インスティテュート | 乳癌におけるカゼインキナーゼ1δの治療標的化 |
WO2017079765A1 (en) | 2015-11-06 | 2017-05-11 | Samumed, Llc | Treatment of osteoarthritis |
CN105646496B (zh) * | 2016-01-20 | 2018-07-20 | 华侨大学 | 一种7H-吡咯并[2,3-d]嘧啶衍生物、其合成方法及应用 |
CN108727400B (zh) * | 2017-05-24 | 2021-07-09 | 四川晶华生物科技有限公司 | 一种***的化合物 |
MX2020004981A (es) * | 2017-10-27 | 2020-08-24 | Bayer Ag | Novedosos derivados de pirazolo-pirrolo-pirimidina como inhibidores de p2x3. |
SG11202005983TA (en) * | 2017-12-28 | 2020-07-29 | Dev Ct Biotechnology | Heterocycle compounds as tyro3, axl and mertk (tam) family of receptor tyrosine kinase inhibitors |
KR102577242B1 (ko) | 2017-12-28 | 2023-09-11 | 주식회사 대웅제약 | 카이네이즈 저해제로서의 아미노-메틸피페리딘 유도체 |
AU2018394997B2 (en) | 2017-12-28 | 2021-02-04 | Daewoong Pharmaceutical Co., Ltd. | Oxy-fluoropiperidine derivative as kinase inhibitor |
CA3099919A1 (en) * | 2018-05-15 | 2019-11-21 | University Of Tennessee Research Foundation | Compounds for treatment of triple negative breast cancer |
US20230000842A1 (en) | 2019-01-17 | 2023-01-05 | Samumed, Llc | Methods of treating cartilage disorders through inhibition of clk and dyrk |
EP4332104A1 (en) * | 2021-04-30 | 2024-03-06 | Wigen Biomedicine Technology (Shanghai) Co., Ltd. | Fused ring compound as wee-1 inhibitor, and preparation method therefor and use thereof |
WO2022235054A1 (ko) * | 2021-05-03 | 2022-11-10 | 주식회사 제이비케이랩 | 2,6-디클로로-4-(4-(4-하이드록시사이클로헥실아미노)-7h-피롤로[2,3-d]피리미딘-5-일)페놀을 유효성분으로 포함하는 암의 예방, 개선 또는 치료용 약학적 조성물 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3507866A (en) | 1967-08-08 | 1970-04-21 | Merck & Co Inc | 1h - imidazo(4,5-b)pyrazin - 2 - one and processes for their preparation |
US3567725A (en) | 1968-11-20 | 1971-03-02 | Merck & Co Inc | Process for preparation of 1h-imidazo-(4,5-b)pyrazin-2-ones |
US4294837A (en) | 1980-03-28 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]pyridine-2-thiones and their cardiotonic use |
US4294836A (en) | 1980-03-24 | 1981-10-13 | Sterling Drug Inc. | 1,3-Dihydro-6-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones and -imidazo[4,5-b]-pyridine-2-thiones and their cardiotonic use |
US4317909A (en) | 1980-03-24 | 1982-03-02 | Sterling Drug Inc. | Preparation of 1,3-dihydro-5-(pyridinyl)-2H-imidazo[4,5-b]pyridin-2-ones |
US4309537A (en) | 1980-03-28 | 1982-01-05 | Sterling Drug Inc. | Production of imidazo[4,5-b]pyridin-2-ones or thiones |
GB8709448D0 (en) | 1987-04-21 | 1987-05-28 | Pfizer Ltd | Heterobicyclic quinoline derivatives |
JPS63275582A (ja) | 1987-05-02 | 1988-11-14 | Naade Kenkyusho:Kk | 2−アミノイミダゾ〔4,5−b〕ピリジン誘導体の製造方法 |
DD262026A1 (de) | 1987-07-10 | 1988-11-16 | Akad Wissenschaften Ddr | Verfahren zur herstellung von 4-substituierten 6-(pyrid-4-yl)-2,4-dihydro-1h-imidazo[4,5-b]pyrid-2-onen |
FR2643903A1 (fr) | 1989-03-03 | 1990-09-07 | Union Pharma Scient Appl | Nouveaux derives de benzimidazole, leurs procedes de preparation, intermediaires de synthese, compositions pharmaceutiques les contenant, utiles notamment pour le traitement des maladies cardiovasculaires, et des ulceres duodenaux |
US4963561A (en) | 1990-02-28 | 1990-10-16 | Sterling Drug Inc. | Imidazopyridines, their preparation and use |
TW274550B (es) | 1992-09-26 | 1996-04-21 | Hoechst Ag | |
DE19601627A1 (de) | 1996-01-18 | 1997-07-24 | Bayer Ag | Heteroatomhaltige Cyclopentanopyridyl-Oxazolidinone |
US6031105A (en) | 1996-04-09 | 2000-02-29 | Pfizer Inc | Substituted pyridines |
DE69827516T2 (de) | 1997-09-26 | 2005-12-01 | Zentaris Gmbh | Azabenzimidazol-verbindungen zur modulation der serin/threonin protein-kinase funktion |
ZA9810490B (en) | 1997-12-03 | 1999-05-20 | Dainippon Pharmaceutical Co | 2-Aryl-8-oxodihydropurine derivative process for the preparation thereof pharmaceutical composition containing the same and intermediate therefor |
JP2003146987A (ja) | 1999-05-31 | 2003-05-21 | Dainippon Pharmaceut Co Ltd | 2−アリールプリン−9−アセトアミド誘導体 |
JP3814125B2 (ja) | 1999-06-02 | 2006-08-23 | 大日本住友製薬株式会社 | 2−アリール−8−オキソジヒドロプリン誘導体からなる医薬 |
JP2002100363A (ja) | 2000-09-25 | 2002-04-05 | Mitsubishi Chemicals Corp | リチウム二次電池用正極材料、リチウム二次電池用正極及びリチウム二次電池 |
JP2002167387A (ja) | 2000-11-29 | 2002-06-11 | Dainippon Pharmaceut Co Ltd | 2−(7,8−ジヒドロ−8−オキソ−9h−プリン−9−イル)酢酸誘導体 |
EP1347982B1 (en) | 2000-12-12 | 2005-11-16 | Neurogen Corporation | Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
WO2002076954A1 (en) | 2001-03-23 | 2002-10-03 | Smithkline Beecham Corporation | Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases |
PL369740A1 (en) | 2001-09-04 | 2005-05-02 | Boehringer Ingelheim Pharma Gmbh & Co.Kg | Novel dihydropteridinones, method for producing the same and the use thereof as medicaments |
JP2005506350A (ja) | 2001-10-18 | 2005-03-03 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | サイトカイン阻害薬としての1,4−二置換ベンゾ−縮合尿素化合物 |
US7247621B2 (en) | 2002-04-30 | 2007-07-24 | Valeant Research & Development | Antiviral phosphonate compounds and methods therefor |
AU2003232071A1 (en) | 2002-05-06 | 2003-11-17 | Genelabs Technologies, Inc. | Nucleoside derivatives for treating hepatitis c virus infection |
AU2003299531A1 (en) | 2002-08-05 | 2004-06-07 | University Of Massachusetts | Compounds for modulating rna interference |
JP2006512313A (ja) | 2002-10-31 | 2006-04-13 | アムジェン インコーポレイテッド | 抗炎症剤 |
WO2004065378A1 (en) | 2003-01-17 | 2004-08-05 | Warner-Lambert Company Llc | 2-aminopyridine substituted heterocycles as inhibitors of cellular proliferation |
MXPA05009068A (es) | 2003-02-26 | 2005-10-19 | Boehringer Ingelheim Pharma | Dihidro-pteridinonas, metodo para la produccion y uso del mismo en la forma de farmacos. |
GB2400101A (en) | 2003-03-28 | 2004-10-06 | Biofocus Discovery Ltd | Compounds capable of binding to the active site of protein kinases |
EP1615669A2 (en) | 2003-04-23 | 2006-01-18 | Wyeth Holdings Corporation | Peg-wortmannin conjugates |
ES2726998T3 (es) | 2003-05-30 | 2019-10-11 | Gilead Pharmasset Llc | Análogos de nucleósidos fluorados modificados |
CA2529196A1 (en) | 2003-06-26 | 2005-02-17 | Merck & Co., Inc. | Benzodiazepine cgrp receptor antagonists |
CA2569406A1 (en) | 2004-06-04 | 2005-12-22 | Icos Corporation | Methods for treating mast cell disorders |
DE102004029784A1 (de) | 2004-06-21 | 2006-01-05 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 2-Benzylaminodihydropteridinone, Verfahren zur deren Herstellung und deren Verwendung als Arzneimittel |
WO2006001266A1 (ja) | 2004-06-23 | 2006-01-05 | Banyu Pharmaceutical Co., Ltd. | 2-アリールプリン誘導体の製造方法 |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
JP2008514628A (ja) | 2004-09-24 | 2008-05-08 | ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ | 蛋白質キナーゼ類のイミダゾ{4,5−b}ピラジノン阻害剤 |
KR20070085286A (ko) | 2004-10-29 | 2007-08-27 | 티보텍 파마슈티칼즈 리미티드 | Hiv를 저해하는 바이사이클릭 피리미딘 유도체 |
US7855205B2 (en) | 2004-10-29 | 2010-12-21 | Janssen Pharmaceutica Nv | Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders |
SE0403006D0 (sv) | 2004-12-09 | 2004-12-09 | Biovitrum Ab | New compounds |
AU2005316668B2 (en) | 2004-12-13 | 2012-09-06 | Millennium Pharmaceuticals, Inc. | Pyrido pyrimidinones, dihydro pyrimido pyrimidinones and pteridinones useful as RAF kinase inhibitors |
JP5001179B2 (ja) | 2005-02-16 | 2012-08-15 | アストラゼネカ アクチボラグ | 化学物質 |
WO2006091737A1 (en) | 2005-02-24 | 2006-08-31 | Kemia, Inc. | Modulators of gsk-3 activity |
KR20080013886A (ko) | 2005-04-05 | 2008-02-13 | 파마코페이아, 인코포레이티드 | 면역억제용 퓨린 및 이미다조피리딘 유도체 |
US20090281075A1 (en) | 2006-02-17 | 2009-11-12 | Pharmacopeia, Inc. | Isomeric purinones and 1h-imidazopyridinones as pkc-theta inhibitors |
PL2583970T3 (pl) | 2006-08-02 | 2016-05-31 | Cytokinetics Inc | Określone cząstki chemiczne, kompozycje i sposoby zawierające imidazopirymidyny |
US20100144738A1 (en) | 2006-09-05 | 2010-06-10 | William Bornmann | Inhibitors of c-met and uses thereof |
AU2007338601C1 (en) | 2006-09-05 | 2014-07-24 | Emory University | Tyrosine kinase inhibitors for prevention or treatment of infection |
US7902187B2 (en) | 2006-10-04 | 2011-03-08 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
AR063142A1 (es) | 2006-10-04 | 2008-12-30 | Pharmacopeia Inc | Derivados de 2-(bencimidazolil) purina y purinonas 6-sustituidas utiles como inmunosupresores,y composiciones farmaceuticas que los contienen. |
MX337906B (es) | 2006-10-19 | 2016-03-28 | Signal Pharm Llc | Compuestos de heteroarilo, composiciones de los mismos, y su uso como inhibidores de proteina cinasas. |
NZ576279A (en) | 2006-10-19 | 2011-12-22 | Signal Pharm Llc | Heteroaryl compounds, compositions thereof, and use thereof as protein kinase inhibitors |
JP2011507910A (ja) | 2007-12-21 | 2011-03-10 | ユニバーシティー オブ ロチェスター | 真核生物の寿命を変更するための方法 |
CA2721072A1 (en) | 2008-04-11 | 2009-10-15 | Bionovo, Inc. | Anticancer methods employing extracts of gleditsia sinensis lam |
CA2723185A1 (en) * | 2008-04-22 | 2009-10-29 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
US8110578B2 (en) | 2008-10-27 | 2012-02-07 | Signal Pharmaceuticals, Llc | Pyrazino[2,3-b]pyrazine mTOR kinase inhibitors for oncology indications and diseases associated with the mTOR/PI3K/Akt pathway |
EP3037421A3 (en) | 2008-11-25 | 2016-11-30 | University Of Rochester | Mlk inhibitors and methods of use |
SG10201500511TA (en) | 2009-10-26 | 2015-03-30 | Signal Pharm Llc | Methods Of Synthesis And Purification Of Heteroaryl Compounds |
UA110697C2 (uk) | 2010-02-03 | 2016-02-10 | Сігнал Фармасьютікалз, Елелсі | ЗАСТОСУВАННЯ ІНГІБІТОРІВ TOR-КІНАЗИ ДЛЯ ЛІКУВАННЯ ПУХЛИННИХ ЗАХВОРЮВАНЬ У ПАЦІЄНТА ЗІ ЗНИЖЕНИМ РІВНЕМ БІЛКА pAMPK ТА/АБО АКТИВНОСТІ AMPK |
US20120028972A1 (en) | 2010-07-30 | 2012-02-02 | Lilly Wong | Biomarker assays for detecting or measuring inhibition of tor kinase activity |
CA2843887A1 (en) | 2011-08-03 | 2013-02-07 | Signal Pharmaceuticals, Llc | Identification of gene expression profile as a predictive biomarker for lkb1 status |
CN103814030A (zh) | 2011-09-22 | 2014-05-21 | 辉瑞大药厂 | 吡咯并嘧啶及嘌呤衍生物 |
KR101978537B1 (ko) | 2011-10-19 | 2019-05-14 | 시그날 파마소티칼 엘엘씨 | Tor 키나제 억제제를 사용한 암의 치료 |
JP6076370B2 (ja) | 2011-12-02 | 2017-02-08 | シグナル ファーマシューティカルズ,エルエルシー | 7−(6−(2−ヒドロキシプロパン−2−イル)ピリジン−3−イル)−1−((トランス)−4−メトキシシクロヘキシル)−3,4−ジヒドロピラジノ[2,3−b]ピラジン−2(1H)−オンの薬剤組成物、その固体形態、およびその使用方法 |
ES2742398T3 (es) | 2012-02-24 | 2020-02-14 | Signal Pharm Llc | Métodos para tratar el cáncer de pulmón no microcítico usando una terapia de combinación de inhibidores de TOR quinasa |
CA2867349A1 (en) | 2012-03-15 | 2013-09-19 | Signal Pharmaceuticals, Llc | Treatment of cancer with tor kinase inhibitors |
SG11201405686PA (en) | 2012-03-15 | 2014-10-30 | Signal Pharm Llc | Treatment of cancer with tor kinase inhibitors |
EP2825170B1 (en) | 2012-03-15 | 2018-05-09 | Signal Pharmaceuticals, LLC | Treatment of cancer with tor kinase inhibitors |
JP6215938B2 (ja) | 2012-08-06 | 2017-10-18 | エイシア バイオサイエンシーズ インコーポレイテッド | プロテインキナーゼの阻害剤としての新規ピロロピリミジン化合物 |
AU2013202768B2 (en) | 2012-10-18 | 2015-11-05 | Signal Pharmaceuticals, Llc | Treatment of cancer with TOR kinase inhibitors |
AU2013203714B2 (en) | 2012-10-18 | 2015-12-03 | Signal Pharmaceuticals, Llc | Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity |
SG11201505446WA (en) | 2013-01-16 | 2015-08-28 | Signal Pharm Llc | Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith |
-
2014
- 2014-01-15 SG SG11201505446WA patent/SG11201505446WA/en unknown
- 2014-01-15 MX MX2015009209A patent/MX2015009209A/es unknown
- 2014-01-15 CN CN201480015876.1A patent/CN105188704B/zh not_active Expired - Fee Related
- 2014-01-15 CA CA2897985A patent/CA2897985A1/en not_active Abandoned
- 2014-01-15 JP JP2015553794A patent/JP2016505041A/ja active Pending
- 2014-01-15 NZ NZ630467A patent/NZ630467A/en not_active IP Right Cessation
- 2014-01-15 AU AU2014207641A patent/AU2014207641A1/en not_active Abandoned
- 2014-01-15 TW TW103101537A patent/TW201441227A/zh unknown
- 2014-01-15 US US14/155,498 patent/US9346812B2/en active Active
- 2014-01-15 US US14/155,485 patent/US9428509B2/en active Active
- 2014-01-15 EA EA201591327A patent/EA201591327A1/ru unknown
- 2014-01-15 AR ARP140100151A patent/AR094494A1/es unknown
- 2014-01-15 BR BR112015016997A patent/BR112015016997A2/pt not_active IP Right Cessation
- 2014-01-15 EP EP14702393.1A patent/EP2945636B1/en not_active Not-in-force
- 2014-01-15 KR KR1020157022134A patent/KR20150108389A/ko not_active Application Discontinuation
- 2014-01-15 PE PE2015001346A patent/PE20151995A1/es not_active Application Discontinuation
- 2014-01-15 ES ES14702393T patent/ES2638179T3/es active Active
- 2014-01-15 WO PCT/US2014/011612 patent/WO2014113429A2/en active Application Filing
- 2014-01-15 EP EP17152166.9A patent/EP3202403A1/en not_active Withdrawn
-
2015
- 2015-07-12 IL IL239901A patent/IL239901A0/en unknown
- 2015-07-13 ZA ZA2015/05011A patent/ZA201505011B/en unknown
- 2015-07-15 CL CL2015001990A patent/CL2015001990A1/es unknown
- 2015-07-15 NI NI201500094AA patent/NI201500094A/es unknown
- 2015-07-15 PH PH12015501576A patent/PH12015501576A1/en unknown
- 2015-07-16 EC ECIEPI201530799A patent/ECSP15030799A/es unknown
-
2016
- 2016-01-04 HK HK16100005.5A patent/HK1212207A1/xx unknown
- 2016-07-21 US US15/215,728 patent/US9795607B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
CN105188704B (zh) | 2017-09-19 |
TW201441227A (zh) | 2014-11-01 |
EP2945636B1 (en) | 2017-06-28 |
EA201591327A1 (ru) | 2015-12-30 |
BR112015016997A2 (pt) | 2017-07-11 |
AU2014207641A1 (en) | 2015-08-06 |
SG11201505446WA (en) | 2015-08-28 |
WO2014113429A3 (en) | 2014-10-09 |
US9428509B2 (en) | 2016-08-30 |
HK1212207A1 (en) | 2016-06-10 |
PH12015501576A1 (en) | 2016-02-01 |
ES2638179T3 (es) | 2017-10-19 |
CL2015001990A1 (es) | 2016-01-22 |
ZA201505011B (en) | 2016-11-30 |
MX2015009209A (es) | 2016-03-17 |
US9346812B2 (en) | 2016-05-24 |
CN105188704A (zh) | 2015-12-23 |
NZ630467A (en) | 2017-02-24 |
US20140200206A1 (en) | 2014-07-17 |
WO2014113429A2 (en) | 2014-07-24 |
EP3202403A1 (en) | 2017-08-09 |
ECSP15030799A (es) | 2015-11-30 |
NI201500094A (es) | 2015-09-21 |
JP2016505041A (ja) | 2016-02-18 |
IL239901A0 (en) | 2015-08-31 |
CA2897985A1 (en) | 2014-07-24 |
KR20150108389A (ko) | 2015-09-25 |
US9795607B2 (en) | 2017-10-24 |
PE20151995A1 (es) | 2016-01-13 |
US20140200207A1 (en) | 2014-07-17 |
US20160324861A1 (en) | 2016-11-10 |
EP2945636A2 (en) | 2015-11-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR094494A1 (es) | Pirrolopirimidinas sustituidas, sus composiciones, y sus métodos de tratamiento | |
CR20160523A (es) | Compuestos de imidazo[4,5-c]quinolin-2-ona y su uso para tratar cáncer | |
PH12017500276A1 (en) | Aminopyrimidinyl compounds as jak inhibitors | |
MX2017007748A (es) | Compuestos de heteroarilo anulares fusionados y su uso como inhibidores del receptor de la tirocina cinasa (trk). | |
AR102171A1 (es) | Compuestos sustituidos de aminopurina, sus composiciones y su uso en el tratamiento o prevención de melanoma | |
AR105238A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
CO2017012067A2 (es) | Derivado de pirido[3,4–d]pirimidina y sal farmacéuticamente aceptable de éste | |
MY180083A (en) | Tetrahydropyrrolothiazine compounds | |
MY192521A (en) | Bicyclic-fused heteroaryl or aryl compounds and their use as irak4 inhibitors | |
AR101174A1 (es) | Imidazopirazinas como inhibidores de lsd1 | |
SG10201811204RA (en) | Bicyclic heterocyclyl derivatives as irak4 inhibitors | |
RS54492B1 (en) | KINASE INHIBITOR REGULATING THE SIGNAL PATH OF APOPTOSIS | |
MX2016010572A (es) | Compuestos heterociclicos aromaticos como compuestos antiinflamatorios. | |
PE20161443A1 (es) | Compuestos | |
EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
MA40059A (fr) | Inhibiteurs de la phosphatidylinositol 3-kinase | |
RS54730B1 (sr) | Inhibitori beta sekretaze | |
RS54526B1 (en) | USE OF PIRAZOLOSPIROKETONE DERIVATIVES AS ACETYL-COA CARBOXYLASE INHIBITORS | |
AR097082A1 (es) | Compuestos terapéuticamente activos y sus métodos de uso | |
CY1125004T1 (el) | Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας | |
EA201691600A1 (ru) | Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений | |
EA201691670A1 (ru) | Тетразолонзамещенные дигидропиридиноновые ингибиторы mgat2 | |
MA39866A (fr) | Amides 2-amino-6-méthyl-4,4a,5,6-tétrahydropyrano[3,4-d][1,3]thiazin-8a(8h)-yl-1,3-thiazol-4-yle | |
WO2014106800A8 (en) | Substituted 2-amino pyrimidine derivatives as kinase inhibitors | |
MX2015015841A (es) | Compuestos de fenoxietil dihidro-1h-isoquinolina. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |